I came across Trinity done time ago - investors need to understand that Philips was never going to be the only device. I am sure mixngo could greatly improve their tests and reduce their costs. This only shows that competition in this space is heating up. This is when the value of mixngo will start to be proven and will work in our favour IMO. If Philips launches a device that has major advantages over say the meritas device then mixngo's value becomes even more sort after. Philips is presenting on the magnotech device at the sony conference tomorrow in Europe. I wonder if someone will want exclusivity for mixngo in the point of care troponin market?
(20min delay)